Cytokinetics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
With a market cap of 7.84B, Cytokinetics(CYTK) trades at $64.08. The stock has a price-to-earnings ratio of -10.03.
On 2025-12-24, Cytokinetics(CYTK) stock moved within a range of $63.20 to $65.28. With shares now at $64.08, the stock is trading +1.4% above its intraday low and -1.8% below the session's peak.
Trading volume for Cytokinetics(CYTK) stock has reached 1.15M, versus its average volume of 2.47M.
The stock's 52-week range extends from a low of $29.31 to a high of $70.98.
The stock's 52-week range extends from a low of $29.31 to a high of $70.98.
CYTK News
New insider activity at Cytokinetics ( (CYTK) ) has taken place on December 23, 2025. Claim 70% Off TipRanks This Holiday Season Unlock hedge-fund level data an...
Leerink raised the firm’s price target on Cytokinetics (CYTK) to $83 from $73 and keeps an Outperform rating on the shares. The firm is updating its model to re...
Cytokinetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the st...
Analyst ratings
81%
of 21 ratingsMore CYTK News
Cytokinetics has secured U.S. FDA approval for MYQORZO (aficamten) tablets to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, its first a...
(RTTNews) - Cytokinetics, Inc. (CYTK) announced that the U.S. Food and Drug Administration has approved MYQORZO (aficamten) tablets in 5 mg, 10 mg, 15 mg, and 2...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
16:20 EST Cytokinetics (CYTK) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>...
Key Points Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500....
Technology Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms Licensing Cytokinetics (CYTK) is on the cusp of its first Food and Drug Adminis...
